Respiratory Tract Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
Lung microbiome: new insights into the pathogenesis of respiratory diseases.
The sirtuin family in health and disease.
Symptoms, complications and management of long COVID: a review.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q3 2027.
Clinical MilestonesViewHide
- 2026-07-17A Phase II Study of Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Results expected Q3 2027
- 2026-05-22Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority TrialResults expected Q2 2028
- 2026-06-30A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung CancerPrimary completion
- 2026-06-03A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, 4-PERIOD, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY AND EFFECT OF FOOD FOLLOWING ORAL ADMINISTRATION OF A NEW TABLET FORMULATION RELATIVE TO THE ORIGINAL FORMULATION OF IBUZATRELVIR IN HEALTHY ADULT PARTICIPANTSPrimary completion
- 2026-07-17ClinicalA Phase II Study of Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Results expected Q3 2027
- 2026-06-30ClinicalA Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung CancerPrimary completion
- 2026-06-03ClinicalA PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, 4-PERIOD, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY AND EFFECT OF FOOD FOLLOWING ORAL ADMINISTRATION OF A NEW TABLET FORMULATION RELATIVE TO THE ORIGINAL FORMULATION OF IBUZATRELVIR IN HEALTHY ADULT PARTICIPANTSPrimary completion
- 2026-05-22ClinicalClinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority TrialResults expected Q2 2028
- 2025-09-05ClinicalA Phase III, Multi-centre, Randomized, Rater- and Patient-blind, Placebo- and Active-controlled, Parallel Group Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily (Active Test Treatment), Ambroxol Hydrochloride 30 mg Twice Daily (Active Control Treatment) and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus SecretionsResults posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Respiratory Tract Diseases4
- Cardiovascular Diseases2
- Neoplasms2
- Coronavirus Infections1
- COVID-191
- Diabetes Mellitus1
- Immune Checkpoint Inhibitors1
- Immunity1
Leading journals6
- Signal transduction and targeted therapy2
- Chest1
- Critical care medicine1
- Environmental health and preventive medicine1
- Frontiers in cellular and infection microbiology1
- International journal of biological sciences1
Leading researchers8
- Abramson M1
- Adjei AA1
- Aiyegbusi OL1
- Altes T1
- Anderson DJ1
- Arjun UVNV1
- Bakker J1
- Balakrishnan A1
Affiliations (unnormalised)6
- Althaia Foundation - Healthcare and University Network1
- Ankara University School of Medicine1
- Austin Hospital and University of Melbourne1
- Beijing Friendship Hospital1
- Biomedical Research Institute Sant Pau (IIB Sant Pau)1
- Birmingham Community Healthcare NHS Foundation Trust1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Respiratory tract diseases are diseases involving the respiratory system. The supplied grounding treats this as a broad category rather than a single specific disorder, and the literature cited focuses on respiratory disease diagnosis, virology, and complications.
The grounding supports several biological themes relevant to respiratory diseases, including microbiota-related host-microbe and microbe-microbe interactions, oxidative stress, and inflammatory signaling. The lung microbiome is described as dynamic and shaped by clearance mechanisms such as coughing, pulmonary macrophages, ciliary activity, and alveolar surfactant, with disruption of these interactions implicated in disease evolution.
The grounding supports prenatal exposure to fine and ultrafine particulate matter as a risk factor for adverse respiratory outcomes in children. Periodontitis is also reported as independently associated with respiratory diseases, indicating an association with increased risk or burden.
For respiratory disease complications such as long COVID, the literature describes multidisciplinary care with long-term monitoring of symptoms. More generally, the grounding does not support a single standard treatment for all respiratory tract diseases, but it does indicate interest in therapeutic targeting of pathways such as sirtuins in respiratory disease.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Diseases involving the RESPIRATORY SYSTEM.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.